Novavax NVAX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.84M-118% | $440.3M+335% | $341.75M+220% | $422.82M+244% | $478.7M+220% | ||
| $22.34M-50.0% | $27.61M-43.1% | $35.01M-25.2% | $41.12M-9.4% | $44.69M+0.8% | ||
| $33.45M-28.6% | $36.02M-25.2% | $38.5M-27.9% | $42M-32.3% | $46.88M-31.3% | ||
| $98.46M— | $98.19M+5,783% | $97.39M+1,258% | $349K+104% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| -$170.8M+51.0% | -$322.57M+21.1% | -$343.49M+13.3% | -$316.96M— | -$348.34M— | ||
| —— | —— | -$113.89M— | —— | —— | ||
| —— | —— | —— | —— | $2.57M— | ||
| -$69.9M— | -$622.94M— | —— | —— | —— | ||
| —— | —— | —— | -$630.94M-4,519% | -$189.21M+59.9% | ||
| $5.36M-31.0% | $5.69M-56.4% | $5.54M-72.2% | $4.9M-86.7% | $7.77M-81.0% | ||
| —— | —— | —— | —— | —— | ||
| $458.02M-5.9% | $353.74M-20.2% | $593.07M+462% | $598.18M— | $486.55M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $8.45M+44.8% | $10.07M+152% | $6.55M+84.2% | $6.08M+99.7% | $5.84M+86.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$3.08M-153% | $2.29M-75.0% | -$5.78M-166% | ||
| -$59.93M+72.4% | -$303.62M-688% | -$319.61M-311% | -$426.58M— | -$217.46M— | ||
| $18.54M-3.3% | $15.05M-14.4% | $21.19M+50.3% | $20.2M+52.6% | $19.17M+59.9% | ||
| $9.15M+263% | $8.81M+828% | $9.11M+1,196% | $6.52M+1,211% | $2.52M+2,017% | ||
| —— | $0-100% | $12.99M-66.7% | $25.97M0.0% | $38.96M+200% | ||
| —— | —— | —— | —— | $3.1M-63.9% | ||
| -$69.9M— | -$622.94M— | —— | —— | —— | ||
| —— | —— | -$113.89M— | —— | —— | ||
| —— | —— | —— | —— | $2.57M— | ||
| $1.67M-86.6% | $1.95M-90.7% | $3M-92.9% | $3.88M-93.4% | $12.44M-81.8% | ||
| $5.36M-31.0% | $5.69M-56.4% | $5.54M-72.2% | $4.9M-86.7% | $7.77M-81.0% | ||
| $458.02M-5.9% | $353.74M-20.2% | $593.07M+462% | $598.18M— | $486.55M— | ||
| —— | $0-100% | $48.16M-66.7% | $96.32M0.0% | $144.48M+200% | ||
| —— | —— | —— | —— | $0— | ||
| $8.45M+44.8% | $10.07M+152% | $6.55M+84.2% | $6.08M+99.7% | $5.84M+86.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$4.8M-468% | -$3.27M-421% | -$1.75M-339% | -$220.75K-150% | ||
| $9.15M+263% | $8.81M+828% | $9.11M+1,196% | $6.52M+1,211% | $2.52M+2,017% | ||
| —— | —— | —— | -$635.71M-2,729% | -$196.98M+61.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Novavax generate?
- Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
- What is Novavax's free cash flow?
- After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
- Where does Novavax's cash flow data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
